-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

Benzinga·09/10/2026 13:11:54
语音播报
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.